News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
689,431 Results
Type
Article (39746)
Company Profile (290)
Press Release (649395)
Section
Business (204220)
Career Advice (2008)
Deals (35401)
Drug Delivery (89)
Drug Development (80976)
Employer Resources (168)
FDA (16124)
Job Trends (14866)
News (345142)
Policy (32483)
Tag
Academia (2558)
Alliances (49282)
Alzheimer's disease (1270)
Approvals (16072)
Artificial intelligence (145)
Bankruptcy (352)
Best Places to Work (11628)
Biotechnology (206)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1672)
Cell therapy (282)
Clinical research (64771)
Collaboration (483)
Compensation (260)
COVID-19 (2543)
C-suite (109)
Data (1389)
Diabetes (172)
Diagnostics (6172)
Earnings (84943)
Employer resources (146)
Events (110242)
Executive appointments (395)
FDA (16795)
Funding (428)
Gene therapy (195)
GLP-1 (601)
Government (4339)
Healthcare (18723)
Infectious disease (2635)
Inflammatory bowel disease (111)
Interviews (312)
IPO (16351)
Job creations (3641)
Job search strategy (1426)
Layoffs (419)
Legal (7871)
Lung cancer (197)
Manufacturing (207)
Medical device (13232)
Medtech (13237)
Mergers & acquisitions (19212)
Metabolic disorders (452)
Neuroscience (1597)
NextGen Class of 2024 (6523)
Non-profit (4477)
Northern California (1694)
Obesity (258)
Opinion (184)
Parkinson's disease (98)
Patents (117)
People (56578)
Phase I (20144)
Phase II (28528)
Phase III (21256)
Pipeline (514)
Postmarket research (2564)
Preclinical (8577)
Radiopharmaceuticals (236)
Rare diseases (260)
Real estate (5907)
Regulatory (21684)
Research institute (2330)
Resumes & cover letters (350)
Southern California (1460)
Startups (3577)
United States (15176)
Vaccines (563)
Weight loss (181)
Date
Today (2)
Last 7 days (582)
Last 30 days (2338)
Last 365 days (35259)
2024 (35087)
2023 (40161)
2022 (51251)
2021 (55793)
2020 (54157)
2019 (46605)
2018 (35089)
2017 (32173)
2016 (31586)
2015 (37658)
2014 (31432)
2013 (26463)
2012 (28658)
2011 (29324)
2010 (27378)
Location
Africa (714)
Arizona (195)
Asia (37371)
Australia (6118)
California (3814)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (80212)
Florida (535)
Georgia (135)
Illinois (388)
Indiana (225)
Maryland (626)
Massachusetts (2972)
Michigan (172)
Minnesota (290)
New Jersey (1102)
New York (1083)
North Carolina (744)
Northern California (1694)
Ohio (146)
Pennsylvania (924)
South America (1094)
Southern California (1460)
Texas (548)
Utah (108)
Washington State (400)
689,431 Results for "minerva neurosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.
May 1, 2024
·
6 min read
Press Releases
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
November 5, 2024
·
6 min read
Business
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.
February 22, 2024
·
6 min read
Genetown
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
February 27, 2024
·
6 min read
Press Releases
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 6, 2024
·
6 min read
Business
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported business updates and financial results for the third quarter ended September 30, 2023.
November 7, 2023
·
6 min read
Drug Development
Minerva’s Schizophrenia Candidate Rejected by FDA in Complete Response Letter
The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.
February 27, 2024
·
2 min read
·
Tyler Patchen
Business
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the second quarter ended June 30, 2023.
August 1, 2023
·
7 min read
Business
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported business updates and financial results for the first quarter ended March 31, 2023.
May 15, 2023
·
7 min read
Deals
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Minerva Neurosciences, Inc. today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant.
June 28, 2023
·
4 min read
1 of 68,944
Next
